Stock Events

Stock Events

Tempest Therapeutics 

€0.000000
0
+€0.00+0% 00:00 Today

Statistics

Day High
-
Day Low
-
52W High
-
52W Low
-
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

17AugExpected
Q1 2026
Next
-2.17
-1.53
-0.88
-0.24
Expected EPS
-0.262401
Actual EPS
N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow 3OS.MU. It's not an investment recommendation.
Tesla
15
TSLA
Amazon
15
AMZN
NVIDIA
15
NVDA
AMD
13
AMD

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Bristol-Myers Squibb
BMY
Mkt Cap118.71B
Bristol Myers Squibb is a leading biopharmaceutical company focusing on cancer therapies, directly competing with Tempest Therapeutics' oncology focus.
Merck
MRK
Mkt Cap319.99B
Merck & Co., Inc. is a global healthcare company that develops cancer drugs, competing in the same therapeutic areas as Tempest Therapeutics.
Pfizer
PFE
Mkt Cap138.61B
Pfizer Inc. has a broad portfolio of oncology drugs, making it a direct competitor in the cancer treatment market.
Gilead Sciences
GILD
Mkt Cap162.98B
Gilead Sciences, Inc. is known for its strong presence in the oncology sector, competing with Tempest Therapeutics in developing cancer therapies.
AMGEN
AMGN
Mkt Cap201.93B
Amgen Inc. focuses on human therapeutics, including oncology, which puts it in direct competition with Tempest Therapeutics.
Novartis
NVS
Mkt Cap305.1B
Novartis AG is a multinational pharmaceutical company with a significant focus on oncology, competing in the same market as Tempest Therapeutics.
Roche
RHHBY
Mkt Cap341.62B
Roche Holding AG is a major player in the oncology market, with a wide range of cancer treatments that compete with Tempest Therapeutics.
Astrazeneca
AZN
Mkt Cap302.65B
AstraZeneca PLC has a strong oncology portfolio, making it a key competitor in the cancer therapy market.
Johnson & Johnson
JNJ
Mkt Cap633.19B
Johnson & Johnson, through its pharmaceutical division Janssen, develops cancer drugs, competing with Tempest Therapeutics.
Regeneron Pharmaceuticals
REGN
Mkt Cap68.59B
Regeneron Pharmaceuticals, Inc. is involved in developing treatments for cancer, among other diseases, competing in the oncology space with Tempest Therapeutics.

About

Tempest Therapeutics Inc. is an oncology company, currently in the clinical development phase, dedicated to advancing novel small molecule drugs designed to combat cancer. The firm's pipeline highlights two key therapeutic candidates: TPST-1495, a compound functioning as a dual inhibitor of EP2 and EP4 receptors (which are implicated in prostaglandin E2 signaling), currently undergoing initial human trials for solid tumor indications. The second candidate, TPST-1120, is a targeted blocker of peroxisome proliferator-activated receptor alpha, also progressing through Phase 1 studies for solid tumors. Beyond these clinical assets, Tempest is exploring TREX-1, a pivotal cellular enzyme known for its role in regulating the innate immune response within cancerous growths. Established in 2011, Tempest Therapeutics Inc. is headquartered in South San Francisco, California, having previously operated as a subsidiary of Inception Sciences, Inc.
Show more...
CEO
Dr. Matthew Angel Ph.D.
Employees
24
Country
United States
ISIN
US87978U1088

Listings

MU
DE
3OS0.MU
F
DE
3OS0.F
STU
DE
3OS0.STU
MU
DE
3OS.MU

0 Comments

Share your thoughts

FAQ

What is Tempest Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on Boerse Muenchen exchange Tempest Therapeutics stocks are traded under the ticker 3OS.MU.
When is the next Tempest Therapeutics earnings date?▼
Tempest Therapeutics is going to release the next earnings report on August 17, 2026.
What were Tempest Therapeutics earnings last quarter?▼
3OS.MU earnings for the last quarter are -2.17 EUR per share, whereas the estimation was -0.24 EUR resulting in a -803.57% surprise. The estimated earnings for the next quarter are N/A EUR per share.
How many employees does Tempest Therapeutics have?▼
As of July 10, 2026, the company has 24 employees.
In which sector is Tempest Therapeutics located?▼
Tempest Therapeutics operates in the Health & Wellness sector.
When did Tempest Therapeutics complete a stock split?▼
Tempest Therapeutics has not had any recent stock splits.
Where is Tempest Therapeutics headquartered?▼
Tempest Therapeutics is headquartered in Brisbane, United States.